Immatics N.V. (IMTX) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MeiraGTx (MGTX) has outperformed Immatics N.V. (IMTX) over the past year, gaining 27.4% versus a loss of 20.8%. Over five years, MGTX leads with a -24.2% price change compared with -46.2% for IMTX. Immatics N.V. is the larger company by market cap ($1.12 billion vs $1.01 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | MGTX |
|---|---|---|
| Share price | $7.37 | $10.50 |
| Market cap | $1.12B | $1.01B |
| 1-day change | -1.07% | -2.96% |
| YTD return | -29.05% | +36.10% |
| 1-year return | -20.83% | +27.44% |
| 5-year return | -46.21% | -24.23% |
| P/E ratio (TTM) | — | 12.07 |
| EPS (TTM) | $-1.87 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.41 | $15.35 |
| 52-week low | $7.02 | $6.62 |
| Distance from 52-week high | -40.61% | -31.60% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +139.21% | +164.29% |
| Average volume | 595.07K | 797.37K |
| Shares outstanding | 152.23M | 96.04M |
| Employees | 704 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed IMTX by 48.3 percentage points over the past year.
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 704 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
IMTX vs MGTX FAQ
Which is bigger, Immatics N.V. or MeiraGTx?
Immatics N.V. (IMTX) is larger, with a market capitalization of $1.12B compared with $1.01B for MeiraGTx (MGTX).
Which stock has performed better over the past year, IMTX or MGTX?
MGTX returned +27.44% over the past 12 months, compared with -20.83% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Immatics N.V. and MeiraGTx in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.